Opportunities
Search

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: УНИВЕРСИТЕТСКА МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ "СВ. ИВАН РИЛСКИ" ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: AB „Kelių priežiūra“ | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

Buyer: GWQ ServicePlus AG | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-10

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Buyer: Lesy České republiky, s.p. | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-11

Buyer: INST NAT DES SCIENCES APPLIQUEES LYON | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-12

Buyer: Miljødirektoratet | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-13

Buyer: Cargotor Sp. z o.o. | Notice type: cn-standard | Procedure: comp-dial | Contract: works | Deadline: 2026-11-13

Buyer: SADEV 94 | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-11-13

Buyer: СПЕЦИАЛИЗИРАНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ НА ХЕМАТОЛОГИЧНИ ЗАБОЛЯВАНИЯ ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-13

Buyer: СПЕЦИАЛИЗИРАНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ НА ХЕМАТОЛОГИЧНИ ЗАБОЛЯВАНИЯ ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-13

Buyer: Odense Kommune | Notice type: cn-standard | Procedure: oth-mult | Contract: services | Deadline: 2026-11-13

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this NOFO are expected to be hy...